ONCBeOne MedicinesRunning, no new patients
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
CLL
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 652 (planned)
- Started
- Nov 11, 2023
- Main results expected
- Feb 2032
- Fully finished
- Dec 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Progression Free Survival (PFS）
Measured over: Up to approximately 9 years
Cohort 1: Rate of Undetectable Measurable Residual Disease
Measured over: Up to one and a half years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06073821 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC